Taro and Sun terminate merger plans

Agreement originally announced in August 2012
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
HAWTHORNE, N.Y.& MUMBAI, India—Taro Pharmaceutical IndustriesLtd. and Sun Pharmaceutical Industries Ltd. announced Feb. 8 that they have mutuallyagreed to terminate their merger agreement, announced in August 2012,pursuant to which all shareholders of Taro (other than Sun Pharma andits affiliates) would have received a cash payment of $39.50 per shareupon the closing of the merger.
 
Both of the companies (at the direction of the special committee)agreed that terminating the merger agreement was in the best interest ofthe respective companies and shareholders.
 
Taro is a multinational, science-basedpharmaceutical company, dedicated to meeting the needs of its customersthrough the discovery, development, manufacturing and marketing of thehighest quality healthcare products.
 
Established in 1983, listed since 1994 and headquartered in India, Sunis an international, integrated,specialty pharmaceutical company. It manufactures and markets a largebasket of pharmaceutical formulations as branded generics as well asgenerics in India, the United States and several other markets acrossthe world. In India, the company is a leader in niche therapy areas ofpsychiatry, neurology, cardiology, gastroenterology, orthopedics andophthalmology. Sun Pharma has strong skills in product development,process chemistry, and manufacturing of complex API, as well as dosageforms.
 
SOURCE: Taro and Sun joint news release
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue